Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome

Brain, Behavior, and Immunity

Volumn 52, Issue , 2016, Pages 32-39

  Loebel, Madlen ^a   Grabowski, Patricia ^a   Heidecke, Harald ^b   Bauer, Sandra ^a   Hanitsch, Leif G ^a   Wittke, Kirsten ^a   Meisel, Christian ^a   Reinke, Petra ^a   Volk, Hans Dieter ^a   Fluge, Oystein ^c   Mella, Olav ^c,d   Scheibenbogen, Carmen ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b CellTrend GmbH   (Germany)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF BERGEN   (Norway)

Author keywords

Autoantibodies; Chronic Fatigue Syndrome; GPCR; Rituximab

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; ANGIOTENSIN RECEPTOR; ANTIBODY; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; BETA ADRENERGIC RECEPTOR; CHOLINERGIC RECEPTOR; DOPAMINE RECEPTOR; ENDOTHELIN RECEPTOR; HLA DR ANTIGEN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; MUSCARINIC M4 RECEPTOR; MUSCARINIC RECEPTOR; PEROXIDASE; RITUXIMAB; SEROTONIN RECEPTOR; THYREOPEROXIDASE; UNCLASSIFIED DRUG; ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; IMMUNOGLOBULIN G; NORADRENALIN;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; CHRONIC FATIGUE SYNDROME; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; CONTROLLED STUDY; CROSS REACTION; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNE DYSREGULATION; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOREACTIVITY; INTRACELLULAR SIGNALING; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; B LYMPHOCYTE; BLOOD; CASE CONTROL STUDY; FATIGUE SYNDROME, CHRONIC; IMMUNOLOGY; METABOLISM;

ADRENERGIC AGENTS; ADULT; AUTOANTIBODIES; B-LYMPHOCYTES; CASE-CONTROL STUDIES; CHOLINERGIC AGENTS; COHORT STUDIES; FATIGUE SYNDROME, CHRONIC; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; NOREPINEPHRINE; RECEPTORS, ADRENERGIC, BETA; RECEPTORS, MUSCARINIC; RITUXIMAB;

EID: 84953352222     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2015.09.013     Document Type: Article

References (73)

1. Balint B., Bhatia K. Reopening the case for anti-basal ganglia antibodies (ABGAs): identification of dopamine-2 receptor antibodies associated with movement disorders. Mov. Disorders 2013, 28:733.
2. Bornholz B., Weidtkamp-Peters S., Schmitmeier S., Seidel C.A., Herda L.R., Felix S.B., Lemoine H., Hescheler J., Nguemo F., Schafer C., Christensen M.O., Mielke C., Boege F. Impact of human autoantibodies on beta1-adrenergic receptor conformation, activity, and internalization. Cardiovasc. Res. 2013, 97:472-480.
3. Bornholz B., Roggenbuck D., Jahns R., Boege F. Diagnostic and therapeutic aspects of beta1-adrenergic receptor autoantibodies in human heart disease. Autoimmun. Rev. 2014, 13:954-962.
4. Brenu E.W., van Driel M.L., Staines D.R., Ashton K.J., Ramos S.B., Keane J., Klimas N.G., Marshall-Gradisnik S.M. Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. J. Transl. Med. 2011, 9:81.
5. Cakalaroski K., Ivanovski N., Popov Z., Dohcev S., Kolevski P., Weil B., Lang P. Mono- and oligoclonal immunoglobulin anomalies in kidney transplant patients. Ann. Urol. 2000, 34:340-344.
6. Carruthers B.M., Jain A., De Meirleir K.L. Myalgic encephalomyelitis/chronic fatigue syndrome: clinical working case definition, diagnostic and treatment protocols. J. Chron. Fatigue Syndr. 2003, 7-116.
7. Carruthers B.M., van de Sande M.I., De Meirleir K.L., Klimas N.G., Broderick G., Mitchell T., Staines D., Powles A.C., Speight N., Vallings R., Bateman L., Baumgarten-Austrheim B., Bell D.S., Carlo-Stella N., Chia J., Darragh A., Jo D., Lewis D., Light A.R., Marshall-Gradisbik S., Mena I., Mikovits J.A., Miwa K., Murovska M., Pall M.L., Stevens S. Myalgic encephalomyelitis: international consensus criteria. J. Intern. Med. 2011, 270:327-338.
8. Dale R.C., Merheb V., Pillai S., Wang D., Cantrill L., Murphy T.K., Ben-Pazi H., Varadkar S., Aumann T.D., Horne M.K., Church A.J., Fath T., Brilot F. Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders. Brain 2012, 135:3453-3468.
9. Dandel M., Wallukat G., Potapov E., Hetzer R. Role of beta(1)-adrenoceptor autoantibodies in the pathogenesis of dilated cardiomyopathy. Immunobiology 2012, 217:511-520.
10. Dandel M., Wallukat G., Englert A., Hetzer R. Immunoadsorption therapy for dilated cardiomyopathy and pulmonary arterial hypertension. Atheroscler. Suppl. 2013, 14:203-211.
11. Davila D.F., Donis J.H., Davila L.A., Odreman W.A., de Bellabarba G.A., Villarroel V. Anti-muscarinic autoantibodies and vagal modulation in Chagas disease: positive allosteric modulators vs desensitization and downregulation of M2 cardiac acetylcholine receptors. Int. J. Cardiol. 2008, 123:328-329. author reply 330-322.
12. Dorffel W.V., Felix S.B., Wallukat G., Brehme S., Bestvater K., Hofmann T., Kleber F.X., Baumann G., Reinke P. Short-term hemodynamic effects of immunoadsorption in dilated cardiomyopathy. Circulation 1997, 95:1994-1997.
13. Du Y., Yan L., Wang J., Zhan W., Song K., Han X., Li X., Cao J., Liu H. Beta1-adrenoceptor autoantibodies from DCM patients enhance the proliferation of T lymphocytes through the beta1-AR/cAMP/PKA and p38 MAPK pathways. PLoS ONE 2012, 7:e52911.
14. Faulkner S., Smith A. A longitudinal study of the relationship between psychological distress and recurrence of upper respiratory tract infections in chronic fatigue syndrome. Br. J. Health Psychol. 2008, 13:177-186.
15. Felten D.L., Felten S.Y., Carlson S.L., Olschowka J.A., Livnat S. Noradrenergic and peptidergic innervation of lymphoid tissue. J. Immunol. 1985, 135:755s-765s. (Baltimore, Md.: 1950).
16. Fluge O., Bruland O., Risa K., Storstein A., Kristoffersen E.K., Sapkota D., Naess H., Dahl O., Nyland H., Mella O. Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study. PLoS ONE 2011, 6:e26358.
17. Fluge O., Risa K., Lunde S., Alme K., Rekeland I.G., Sapkota D., Kristoffersen E.K., Sorland K., Bruland O., Dahl O., Mella O. B-Lymphocyte depletion in myalgic encephalopathy/chronic fatigue syndrome. An open-label phase II study with rituximab maintenance treatment. PLoS ONE 2015, 10:e0129898.
18. Frauenknecht K., Katzav A., Grimm C., Chapman J., Sommer C.J. Neurological impairment in experimental antiphospholipid syndrome is associated with increased ligand binding to hippocampal and cortical serotonergic 5-HT1A receptors. Immunobiology 2013, 218:517-526.
19. Freeman R., Komaroff A.L. Does the chronic fatigue syndrome involve the autonomic nervous system?. Am. J. Med. 1997, 102:357-364.
20. Fujii T., Watanabe Y., Inoue T., Kawashima K. Upregulation of mRNA encoding the M5 muscarinic acetylcholine receptor in human T- and B-lymphocytes during immunological responses. Neurochem. Res. 2003, 28:423-429.
21. Galloway A., Li H., Vanderlinde-Wood M., Khan M., Benbrook A., Liles C., Zillner C., Rao V., Cunningham M.W., Yu X., Kem D.C. Activating autoantibodies to the beta1/2-adrenergic and M2 muscarinic receptors associate with atrial tachyarrhythmias in patients with hyperthyroidism. Endocrine 2014.
22. Gilmour J., Brownlee Y., Foster P., Geekie C., Kelly P., Robertson S., Wade E., Braun H.B., Staub U., Michel G., Lazarus J.H., Parkes A.B. The quantitative measurement of autoantibodies to thyroglobulin and thyroid peroxidase by automated microparticle based immunoassays in Hashimoto's disease, Graves' disease and a follow-up study on postpartum thyroid disease. Clin. Lab. 2000, 46:57-61.
23. Gould R.W., Dencker D., Grannan M., Bubser M., Zhan X., Wess J., Xiang Z., Locuson C., Lindsley C.W., Conn P.J., Jones C.K. A role for the M1 muscarinic acetylcholine receptor in top-down cognitive processing using a touchscreen visual discrimination task in mice. ACS Chem. Neurosci. 2015.
24. Grisanti L.A., Evanson J., Marchus E., Jorissen H., Woster A.P., DeKrey W., Sauter E.R., Combs C.K., Porter J.E. Pro-inflammatory responses in human monocytes are beta1-adrenergic receptor subtype dependent. Mol. Immunol. 2010, 47:1244-1254.
25. Gunther J., Kill A., Becker M.O., Heidecke H., Rademacher J., Siegert E., Radic M., Burmester G.R., Dragun D., Riemekasten G. Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients. Arthritis Res. Ther. 2014, 16:R65.
26. Gur A., Oktayoglu P. Central nervous system abnormalities in fibromyalgia and chronic fatigue syndrome: new concepts in treatment. Curr. Pharm. Des. 2008, 14:1274-1294.
27. Herda L.R., Felix S.B., Boege F. Drug-like actions of autoantibodies against receptors of the autonomous nervous system and their impact on human heart function. Br. J. Pharmacol. 2012, 166:847-857.
28. Hoad A., Spickett G., Elliott J., Newton J. Postural orthostatic tachycardia syndrome is an under-recognized condition in chronic fatigue syndrome. QJM 2008, 101:961-965.
29. Jones J.F., Nicholson A., Nisenbaum R., Papanicolaou D.A., Solomon L., Boneva R., Heim C., Reeves W.C. Orthostatic instability in a population-based study of chronic fatigue syndrome. Am. J. Med. 2005, 118:1415.
30. Jones A.L., Mowry B.J., McLean D.E., Mantzioris B.X., Pender M.P., Greer J.M. Elevated levels of autoantibodies targeting the M1 muscarinic acetylcholine receptor and neurofilament medium in sera from subgroups of patients with schizophrenia. J. Neuroimmunol. 2014, 269:68-75.
31. Kavelaars A., Kuis W., Knook L., Sinnema G., Heijnen C.J. Disturbed neuroendocrine-immune interactions in chronic fatigue syndrome. J. Clin. Endocrinol. Metab. 2000, 85:692-696.
32. Klein-Weigel P.F., Bimmler M., Hempel P., Schopp S., Dreusicke S., Valerius J., Bohlen A., Boehnlein J.M., Bestler D., Funk S., Elitok S. G-protein coupled receptor auto-antibodies in thromboangiitis obliterans (Buerger's disease) and their removal by immunoadsorption. VASA 2014, 43:347-352.
33. Klimas N.G., Salvato F.R., Morgan R., Fletcher M.A. Immunologic abnormalities in chronic fatigue syndrome. J. Clin. Microbiol. 1990, 28:1403-1410.
34. Konstantinov K., von Mikecz A., Buchwald D., Jones J., Gerace L., Tan E.M. Autoantibodies to nuclear envelope antigens in chronic fatigue syndrome. J. Clin. Investig. 1996, 98:1888-1896.
35. Labovsky V., Smulski C.R., Gomez K., Levy G., Levin M.J. Anti-beta1-adrenergic receptor autoantibodies in patients with chronic Chagas heart disease. Clin. Exp. Immunol. 2007, 148:440-449.
36. Li H., Yu X., Liles C., Khan M., Vanderlinde-Wood M., Galloway A., Zillner C., Benbrook A., Reim S., Collier D., Hill M.A., Raj S.R., Okamoto L.E., Cunningham M.W., Aston C.E., Kem D.C. Autoimmune basis for postural tachycardia syndrome. J. Am. Heart Assoc. 2014, 3:e000755.
37. Li J., Zhang Q., Liao Y., Zhang C., Hao H., Du J. The value of acetylcholine receptor antibody in children with postural tachycardia syndrome. Pediatr. Cardiol. 2015, 36:165-170.
38. Lin G.G., Li J.M. IgG subclass serum levels in systemic lupus erythematosus patients. Clin. Rheumatol. 2009, 28:1315-1318.
39. Liu Y., Li J. Preferentially immunoglobulin (IgG) subclasses production in primary Sjogren's syndrome patients. Clin. Chem. Lab. Med. 2011.
40. Loebel M., Mooslechner A.A., Bauer S., Guenther S., Letsch A., Hanitsch L.G., Grabowski P., Meisel C., Volk H.D., Scheibenbogen S. Polymorphism in COMT is associated with IgG3 subclass level and susceptibility to infection in patients with Chronic Fatigue Syndrome. J. Transl. Med. 2015, (in press).
41. Muller J., Wallukat G., Dandel M., Bieda H., Brandes K., Spiegelsberger S., Nissen E., Kunze R., Hetzer R. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation 2000, 101:385-391.
42. Nakai A., Hayano Y., Furuta F., Noda M., Suzuki K. Control of lymphocyte egress from lymph nodes through beta2-adrenergic receptors. J. Exp. Med. 2014, 211:2583-2598.
43. Newton D.J., Kennedy G., Chan K.K., Lang C.C., Belch J.J., Khan F. Large and small artery endothelial dysfunction in chronic fatigue syndrome. Int. J. Cardiol. 2012, 154:335-336.
44. Ogawa M., Nishiura T., Yoshimura M., Horikawa Y., Yoshida H., Okajima Y., Matsumura I., Ishikawa J., Nakao H., Tomiyama Y., Kanayama Y., Kanakura Y., Matsuzawa Y. Decreased nitric oxide-mediated natural killer cell activation in chronic fatigue syndrome. Eur. J. Clin. Invest. 1998, 28:937-943.
45. Onouchi H., Muro Y., Tomita Y. Clinical features and IgG subclass distribution of anti-p80 coilin antibodies. J. Autoimmun. 1999, 13:225-232.
46. Pei J., Li N., Chen J., Li X., Zhang Y., Wang Z., Zhang P., Cao K., Pu J. The predictive values of beta1-adrenergic and M2 muscarinic receptor autoantibodies for sudden cardiac death in patients with chronic heart failure. Eur. J. Heart Fail. 2012, 14:887-894.
47. Perilloux B.C., Shetty A.K., Leiva L.E., Gedalia A. Antinuclear antibody (ANA) and ANA profile tests in children with autoimmune disorders: a retrospective study. Clin. Rheumatol. 2000, 19:200-203.
48. Podojil J.R., Sanders V.M. Selective regulation of mature IgG1 transcription by CD86 and beta 2-adrenergic receptor stimulation. J. Immunol. 2003, 170:5143-5151. (Baltimore, Md.: 1950).
49. Reynolds G.K., Lewis D.P., Richardson A.M., Lidbury B.A. Comorbidity of postural orthostatic tachycardia syndrome and chronic fatigue syndrome in an Australian cohort. J. Intern. Med. 2014, 275:409-417.
50. Ribeiro A.L., de Carvalho A.C., Lombardi F., Talvani A., Teixeira M.M., Rocha M.O. In vivo inhibitory effect of anti-muscarinic autoantibodies on the parasympathetic function in Chagas disease. Int. J. Cardiol. 2010, 145:339-340.
51. Schegg V., Vogel M., Didichenko S., Stadler M.B., Beleznay Z., Gadola S., Sengupta C., Stadler B.M., Miescher S.M. Evidence that anti-muscarinic antibodies in Sjogren's syndrome recognise both M3R and M1R. Biologicals 2008, 36:213-222.
52. Schulze W., Kunze R., Wallukat G. Pathophysiological role of autoantibodies against G-protein-coupled receptors in the cardiovascular system. Exp. Clin. Cardiol. 2005, 10:170-172.
53. Skowera A., Cleare A., Blair D., Bevis L., Wessely S.C., Peakman M. High levels of type 2 cytokine-producing cells in chronic fatigue syndrome. Clin. Exp. Immunol. 2004, 135:294-302.
54. Slota C., Shi A., Chen G., Bevans M., Weng N.P. Norepinephrine preferentially modulates memory CD8 T cell function inducing inflammatory cytokine production and reducing proliferation in response to activation. Brain Behav. Immun. 2015, 46:168-179.
55. Stavrakis S., Yu X., Patterson E., Huang S., Hamlett S.R., Chalmers L., Pappy R., Cunningham M.W., Morshed S.A., Davies T.F., Lazzara R., Kem D.C. Activating autoantibodies to the beta-1 adrenergic and m2 muscarinic receptors facilitate atrial fibrillation in patients with Graves' hyperthyroidism. J. Am. Coll. Cardiol. 2009, 54:1309-1316.
56. Steiner J., Schiltz K., Bernstein H.G., Bogerts B. Antineuronal antibodies against neurotransmitter receptors and synaptic proteins in schizophrenia: current knowledge and clinical implications. CNS Drugs 2015, 29:197-206.
57. Strioga M., Pasukoniene V., Characiejus D. CD8+ CD28- and CD8+ CD57+ T cells and their role in health and disease. Immunology 2011, 134:17-32.
58. Sumida T., Tsuboi H., Iizuka M., Asashima H., Matsumoto I. Anti-M3 muscarinic acetylcholine receptor antibodies in patients with Sjogren's syndrome. Mod. Rheumatol. 2013, 23:841-845.
59. Suzuki, S., 2010. [Lambert-Eaton myasthenic syndrome (LEMS)]. Brain and nerve = Shinkei kenkyu no shinpo 62, 419-426.
60. Takamori M., Motomura M., Fukudome T., Yoshikawa H. Autoantibodies against M1 muscarinic acetylcholine receptor in myasthenic disorders. Eur. J. Neurol. 2007, 14:1230-1235.
61. Talvani A., Rocha M.O., Ribeiro A.L., Borda E., Sterin-Borda L., Teixeira M.M. Levels of anti-M2 and anti-beta1 autoantibodies do not correlate with the degree of heart dysfunction in Chagas' heart disease. Microbes Infect. 2006, 8:2459-2464.
62. Tanaka S., Kuratsune H., Hidaka Y., Hakariya Y., Tatsumi K.I., Takano T., Kanakura Y., Amino N. Autoantibodies against muscarinic cholinergic receptor in chronic fatigue syndrome. Int. J. Mol. Med. 2003, 12:225-230.
63. Thiers C.A., Barbosa J.L., Pereira Bde B., Nascimento E.M., Nascimento J.H., Medei E.H., Pedrosa R.C. Autonomic dysfunction and anti-M2 and anti-beta1 receptor antibodies in Chagas disease patients. Arq. Bras. Cardiol. 2012, 99:732-739.
64. Turki J., Liggett S.B. Receptor-specific functional properties of beta 2-adrenergic receptor autoantibodies in asthma. Am. J. Respir. Cell Mol. Biol. 1995, 12:531-539.
65. von Mikecz A., Konstantinov K., Buchwald D.S., Gerace L., Tan E.M. High frequency of autoantibodies to insoluble cellular antigens in patients with chronic fatigue syndrome. Arthritis Rheum. 1997, 40:295-305.
66. Wallukat G., Schimke I. Agonistic autoantibodies directed against G-protein-coupled receptors and their relationship to cardiovascular diseases. Semin. Immunopathol. 2014, 36:351-363.
67. Wheatland R. Chronic ACTH autoantibodies are a significant pathological factor in the disruption of the hypothalamic-pituitary-adrenal axis in chronic fatigue syndrome, anorexia nervosa and major depression. Med. Hypotheses 2005, 65:287-295.
68. Yamamoto S., Ouchi Y., Nakatsuka D., Tahara T., Mizuno K., Tajima S., Onoe H., Yoshikawa E., Tsukada H., Iwase M., Yamaguti K., Kuratsune H., Watanabe Y. Reduction of [11C](+)3-MPB binding in brain of chronic fatigue syndrome with serum autoantibody against muscarinic cholinergic receptor. PLoS ONE 2012, 7:e51515.
69. Yu X., Stavrakis S., Hill M.A., Huang S., Reim S., Li H., Khan M., Hamlett S., Cunningham M.W., Kem D.C. Autoantibody activation of beta-adrenergic and muscarinic receptors contributes to an "autoimmune" orthostatic hypotension. J. Am. Soc. Hypertens. 2012, 6:40-47.
70. Zalli A., Bosch J.A., Goodyear O., Riddell N., McGettrick H.M., Moss P., Wallace G.R. Targeting ss2 adrenergic receptors regulate human T cell function directly and indirectly. Brain Behav. Immun. 2015, 45:211-218.
71. Zhang H., Li P., Wu D., Xu D., Hou Y., Wang Q., Li M., Li Y., Zeng X., Zhang F., Shi Q. Serum IgG subclasses in autoimmune diseases. Medicine 2015, 94:e387.
72. Zhao P., Han Y. Low incidence of positive smooth muscle antibody and high incidence of isolated IgM elevation in Chinese patients with autoimmune hepatitis and primary biliary cirrhosis overlap syndrome: a retrospective study. BMC Gastroenterol. 2012, 12:1.
73. Zhao L.S., Liao Y.H., Xiang G.D., Wang M., Zhou Z.H., Hou J., Le L., Xu L. Autoantibodies against beta1 and M2 receptor in diabetic patients with refractory hypertension. Zhonghua Xin Xue Guan Bing Za Zhi 2006, 34:407-410.